Purdue seeks abuse-deterrent hydrocodone nod in midst of US opioids storm
This article was originally published in Scrip
Executive Summary
Right in the midst of the controversy over the FDA's approval of Zogenix's single-entity, extended-release hydrocodone medicine Zohydro ER, which has had some Capitol Hill lawmakers, state governors and opponents up in arms, Purdue Pharma has submitted a new drug application (NDA) seeking to market what it claims is an abuse-deterrent formulation of the same active ingredient.